| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Kodiak Sciences Inc | KSI-301 - (GLEAM) | Diabetic macular edema (DME) | Phase 3 | Intravitreal | Opthalmic | |
| Kodiak Sciences Inc | KSI-301 - (GLIMMER) | Diabetic Macular Edema (DME) | Phase 3 | Data Released | Intravitreal injection | Opthalmic |
| Kodiak Sciences Inc | KSI-301 - (DAYLIGHT) | Treatment-Naive Wet Age-Related Macular Degeneration (AMD) | Phase 3 | Trial Completed | Intravitreal | Opthalmic |
| Kodiak Sciences Inc | KSI-301 - (BEACON) | Retinal vein occlusion (RVO) | Phase 3 | Data Released | Intravitreal | Opthalmic |
| Kodiak Sciences Inc | KSI-301 - (GLEAM) | Diabetic macular edema (DME) | Phase 3 | Intravitreal | Opthalmic | |
| Kodiak Sciences Inc | KSI-301 - (DAZZLE) | Wet age-related macular degeneration (AMD) | Phase 2/3 | Intravitreal injection | Opthalmic | |
| Korro Bio Inc. | FX-322-208 | Acquired Sensorineural Hearing Loss (SNHL) | Phase 2b | Trial Discontinued | Intratympanic | Neurology |
| Kronos Bio Inc. | Entospletinib - (AGILITY) | Acute myeloid leukemia (AML) | Phase 3 | Trial Discontinued | Oral | Oncology |